Cloughesy and colleagues confirmed that the use of neoadjuvant anti-PD-1 therapy in rGB patients could effectively activate TIL function, produce an IFN-γ response, and inhibit the transcription of tumor cell cycle-related genes and tumor cell proliferation (Fig. 3). The gene discussed is IFNG; the disease is neoplasm.